Schizophrenia Clinical Trials in San Francisco

View 14 new treatments for Schizophrenia in San Francisco, CA, and other areas near me, such as Antioch, Berkeley, Concord, Daly City, Oakland, Richmond and Vallejo. Every day, Power helps hundreds of schiz patients connect with leading medical research.
View 12 trials in San Francisco
Filter (12)

RL-007 for Cognitive Impairment in Schizophrenia

Recognify Life Sciences Clinic, Walnut Creek + 2 more

This trial is testing a new drug, RL-007, to see if it can help people with schizophrenia think and remember better. The study will compare different doses of the drug and check for any side effects. Participants will take the drug for several weeks and complete memory and thinking tests before and after the treatment.Show More

Verified

Recruiting
Phase 2
Est. 3 - 6 Weeks
Gary Walker, PhD
Study Director

KarXT for Schizophrenia

Karuna Clinic, Lafayette + 3 more

This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Bruce Kinon, MD
Study Director

Long-term Safety of Iclepertin for Schizophrenia

Boehringer Ingelheim Clinic, Stanford + 1 more

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

KarXT for Schizophrenia

Karuna Clinic, Lafayette + 4 more

This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Bruce Kinon, MD
Study Director

Valbenazine for Schizophrenia

Neurocrine Clinic, Stanford + 2 more

The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Clinical Development Lead
Study Director

OLZ/SAM for Schizophrenia

Alkermes Clinic, Stanford + 1 more

This trial evaluates the safety and tolerability of OLZ/SAM in children and adolescents with schizophrenia or Bipolar I disorder. OLZ/SAM combines olanzapine to manage symptoms and samidorphan to reduce weight gain. Olanzapine is a well-established antipsychotic effective for schizophrenia and bipolar I disorder, but its use is limited by significant weight gain; samidorphan is added to mitigate this side effect.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
David McDonnell, MD
Study Director

OLZ/SAM vs. Olanzapine for Schizophrenia or Bipolar Disorder

Alkermes Clinic, Stanford + 1 more

To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
David McDonnell, MD
Study Director

Emraclidine for Schizophrenia

Cerevel Clinic, Lafayette + 2 more

This trial aims to evaluate the safety and tolerability of a medication called emraclidine, taken by mouth, in adults with schizophrenia.
Recruiting

No Placebo Trial

Phase 2
Est. 3 - 6 Weeks
Erica Koenig, PhD
Study Director

Synaptic Imaging for Schizophrenia

Research Clinic, Stanford + 2 more

The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer \[11C\]UCB-J to test the neural synaptic pruning hypothesis of schizophrenia. This imaging method allows for the quantification of synaptic density in the living human brain and has the unprecedented ability to directly examine the synaptic pathology underlying neuropsychiatric disease. The neural synaptic pruning hypothesis posits that a key pathogenic process of schizophrenia is the over-exuberant elimination of neural synapses during development. The confirmation of reduced synaptic density in schizophrenia as evidenced by \[11C\]UCB-J has the potential to lead to a number of ground-breaking clinical innovations, such as laboratory-based diagnostics and prognostics, and novel, disease-modifying treatments.Show More
Recruiting

No Placebo Trial

Phase 1
Est. 6 - 12 Weeks
Jong H Yoon, MD
Principal Investigator

TMS for Schizophrenia

Research Clinic, San Francisco + 1 more

This randomized controlled trial in healthy controls (HC) and patients with schizophrenia (SZ) aims to examine 1) the underlying cognitive and neural cause of self-agency deficits in SZ; 2) the responsiveness to a novel navigated repetitive transcranial magnetic stimulation (nrTMS) target in the medial/superior prefrontal cortex (mPFC); and 3) how modulation of mPFC activity impacts the larger self-agency network to mediate changes in self-agency judgments. Our overall hypothesis is that increased mPFC excitability by active high-frequency nrTMS in HC and SZ will induce behavioral improvements in self-agency and neural changes in the larger self-agency network that will generalize to improvements in overall cognition, symptoms and daily functioning, and will likely lead to the development of new effective neuromodulation therapies in patients with schizophrenia.Show More
Recruiting
N/A
Est. 3 - 12 Weeks
Karuna Subramaniam, PhD
Principal Investigator
Page 1 of 2

Frequently Asked Questions

How much do schizophrenia clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do schizophrenia clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across schizophrenia trials in San Francisco, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for schizophrenia patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

What promising new drugs are being tested?

In San Francisco, research for schizophrenia includes Neuromodulation Therapy. A specific treatment being studied is Navigated Repetitive Transcranial Magnetic Stimulation (nrTMS).